Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial

The present analysis provided no evidence of an increase in recurrent stroke associated with larger reductions in systolic BP produced by treatment among patients with cerebrovascular disease

H. Arima; C. Anderson; T. Omae; M. Woodward; S. MacMahon; G. Mancia; M.-G. Bousser; C. Tzourio; S. Harrap; L. Liu; B. Neal; J. Chalmers; for the PROGRESS Collaborative Group

2014

Scholarcy highlights

  • We aimed to determine whether large treatment-related blood pressure reductions are associated with increased risks of recurrent stroke
  • Design Data are from the PROGRESS trial, where 6105 patients with cerebrovascular disease were randomly assigned to either active treatment or placebo(s)
  • BP was measured at every visit, and participant groups defined by reduction in systolic BP from baseline were used for the analyses
  • After adjustment for cardiovascular risk factors and randomised treatment, annual incidence was 2.08%, 2.10%, 2.31% and 2.96% for participant groups defined by SBP reductions of ≥20, 10–19, 0–9 and <0 mm Hg, respectively
  • The present analysis provided no evidence of an increase in recurrent stroke associated with larger reductions in SBP produced by treatment among patients with cerebrovascular disease
  • You will be able to get a quick price and instant permission to reuse the content in many different ways

Need more features? Save interactive summary cards to your Scholarcy Library.